A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and the overall experience of attending the CPHI conference.

Frank Romanski of Lonza Capsugel dives into the excipient side of manufacturing and the emerging prevalence of digitalization.

Andy Studna is an assistant editor for Pharmaceutical Executive and Applied Clinical Trials. He can be reached at [email protected].

3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

In the life sciences industry, the journey from discovery to delivery is only as strong as the supply chain and distribution network behind it. As the industry continues to evolve—driven by advanced ...

Ex vivo lung perfusion (EVLP) provides a platform for testing therapies but faces challenges in standardizing drug evaluation. At AAPS PharmSci 360, Xuanzi Zhou says digital twins accurately predict ...

Siddhant Sojitra, Alexion, defines in an AAPS PharmSci 360 2025 presentation an agitation model to reliably test stability for early-stage biologics.

A streamlined workflow using Six Sigma's DMAIC methodology was developed to identify and mitigate visible particles in biologics, reducing time and resources while maintaining quality.

Biopharma quality control is being revolutionized by advanced analytics and digital transformation through a synergy that boosts quality and scalability.

Steve will be monitoring the Rapid Fires: AI/ML in Bioanalysis session on Monday, Nov. 10, 2025 at 3PM CT at AAPS PharmSci 360 2025, being held Nov. 9–12 in San Antonio, Texas. Click the video above ...